PUBLIC CONTRACT · 2025
Aquisição de TOCILIZUMAB 162 MG/0.9 ML (BIOSSIMILAR FRESENIUS) SOL INJ CANETA, SEINGA 0.9 ML SC
- Contract value
- €114,230.25
- Signed on
- 15 September 2025
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 11720211PUBLISHED DESCRIPTION
41017325 - Aquisição de TOCILIZUMAB 162 MG/0.9 ML (BIOSSIMILAR FRESENIUS) SOL INJ CANETA, SEINGA 0.9 ML SC
WHO CONTRACTED
Parties involved
- Place of performance
- Portugal, Lisboa, Lisboa
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- Fresenius Kabi Pharma Portugal, L · Tax ID 504293753
HOW MUCH AND WHEN
Values and timeline
- Contract price
- €114,230.25
- Procedure base price
- €114,230.25
- Total effective price
- Not reported on Portal BASE
- Publication date
- 15 September 2025
- Award date
- 21 August 2025
- Signing date
- 15 September 2025
- Performance period
- 107 days
The contract price is the value agreed in the contract, not the amount paid.
HOW IT WAS CONTRACTED
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Monofator
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 24.º, n.º 1, alínea e), subalínea ii) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- Not stated
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 7773805
KEEP EXPLORING
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.